LSE:GDR Logo.

genedrive plc
LSE:GDR

GBp 1.08 0 (0%)
EOD - 2026-01-28

Market cap
11.07M
Enterprise value
5.54M
Volume
4.05M
PE
-
50 Day MA
0.94
200 Day MA
1.00
EPS
-0.01
Currency
GBp
Number of Shares
1,029.6M

Learn the Markets
Sector Healthcare
Industry Diagnostics & Research
Employee Count 43
Country United Kingdom
Address Manchester, M13 9XX
Phone +44 16 1989 0245
Socials X.com

genedrive plc Price Highlights 🏷️

1 Day
0%
1 Week
-2.27%
1 Month
30.3%
6 Months
-10.42%
1 Year
-52.22%

genedrive plc Price Chart 📈

Buy and Sell genedrive plc 🛒

EToro

Live Trading

Buy & Sell
Trading 212

Live Trading

Buy & Sell
ShareScope

Paper Trading

Learn How
Investor Returns 👀
£
1 Week
£0
-2.27%
1 Month
+£0
+30.3%
1 Year
£0
-52.22%
genedrive plc Dates 📅
Last Fiscal Year End 2025-06-30
Next Fiscal Year End 2026-06-30
Recent Quarter 2025-06-30
ExDividend Date -
Last Dividend Date -
Last Dividend -

Learn the Markets

Jigglypop Analysis For genedrive plc 🤓


2026-01-16

Genedrive trades at 0.9p, roughly a third up from its 52-week low (0.19p) and well below the 2.4p high, with the price sitting under the 200-day average and hugging the 50-day. That positioning, plus a £9.3m micro-cap and a stated need for near-term financing, frames this firmly as a speculative play rather than a value reset. Operationally, momentum is building: NICE Early Value Assessment is translating into MT-RNR1 usage, Scotland is rolling out neonatal testing, NHS pilots for CYP2C19 are advancing, and a Saudi MoU opens an international pathway. Yet funding clarity remains the swing factor. Expect news-driven volatility; confirmation of financing and NHS procurement traction would de-risk the story, while delays could pressure a still fragile share price further.

About genedrive plc 👋


genedrive plc designs, develops, and manufactures molecular diagnostic testing devices for genotyping, pathogen identification, infectious disease detection, and other clinical applications. Its offerings include the Genedrive system, a rapid nucleic acid thermocycler with fluorescence signal detection for target discrimination used in qualitative in vitro molecular diagnostics; and the Genedrive CYP2C19 ID Kit, a certified assay to identify individuals unlikely to respond to the widely used antiplatelet drug clopidogrel. The company also provides the Genedrive MT-RNR1-ID Kit, a rapid genetic test for emergency neonatal care; assays to detect antibiotic-induced hearing loss in newborns; confirmation of HCV infection prior to therapy; pathogen detection for biological military threats; and a point-of-care COVID-19 testing solution for settings such as healthcare, workplace screening, travel, and antigen test confirmation. It serves the medical, biotechnology, and pharmaceutical sectors in the United Kingdom, Europe, the United States, and globally. Formerly Epistem Holdings Plc, it rebranded to genedrive plc in July 2016. Founded in 2000, it is headquartered in Manchester, United Kingdom.

genedrive plc Price Range 🎯

Low
0.19
Last 52 Weeks
High
2.4
📍
All-time high
GBp 1.15
All-time low
GBp 1.035
Ownership Breakdown 🤝
genedrive plc Consensus.
💰

Brokers Consensus

None
Frequent Asked Questions 💬

LSE:GDR has around 43 people working for the Company.

LSE:GDR belongs to the Healthcare Sector.

The 200 day MA value for genedrive plc is 1.00.

The 50 day MA value for genedrive plc is 0.94.

The ATH price for genedrive plc is 1.15.

The ATL price for genedrive plc is 1.035.

News Bites 🗞️

🚨
Company Update · 05/12/2025
Genedrive reported a narrowed full-year pretax loss as revenue rose, driven by use of its MT-RNR1 test under NICE’s Early Value Assessment. It has visibility on near-term income from NICE evidence submission, Scotland’s phased MT-RNR1 rollout, a CYP2C19 pilot, and a programme at Manchester University NHS Foundation Trust. The company requires near-term financing; a shareholder loan is nearing finalisation.


🚨
Company Update · 01/12/2025
Genedrive reported two posters at the UK Stroke Forum describing lab and near‑patient CYP2C19 testing using its ID kit. The posters said near‑patient testing identified more clopidogrel non‑responders, influenced prescribing, and that implementation was feasible with immediate results, supporting genotype‑guided antiplatelet therapy in stroke/TIA. The CEO said the company plans to progress with NHS integrated care boards and procurement.


🚨
Company Update · 26/11/2025
Genedrive said its MT-RNR1 ID kit will begin use for babies requiring antibiotic treatment at the Royal Hospital for Children, Glasgow, with the Royal Alexandra Hospital and Princess Royal Maternity Hospital to follow, as part of a phased rollout across NHS Scotland neonatal units. It also noted recent media coverage.


🚨
Company Update · 28/10/2025
Genedrive reported that its exclusive Saudi distributor, iDeal iDea for Medical Equipment Technology, signed a memorandum of understanding with Saudi Arabia’s Ministry of Health to pilot the MT-RNR1 ID Kit under the “Generations Hear” initiative, assessing potential national implementation.


Market News

Loading story...

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial, investment, or trading advice. Cryptocurrency and stock investments involve risk, and you should conduct your own research or consult with a qualified financial advisor before making any investment decisions. Past performance does not guarantee future results.
© Jigglypop. All rights reserved.
>